Akums Drugs and Pharmaceuticals, New Delhi-based Contract Development and Manufacturing Organisation (CDMO), has been awarded a patent for its Room Temperature Stable Oral Suspension of Hydroxyurea, a breakthrough formulation aimed at managing Sickle Cell Disease (SCD). This development reinforces Akums' role as an innovator in pharmaceutical solutions, offering a significant advance in addressing the storage and accessibility challenges associated with Hydroxyurea solution.

Sickle Cell Disease, a genetic blood disorder, leads to severe health complications such as anaemia, frequent pain episodes and other debilitating symptoms, affecting millions worldwide especially in India and Africa. Akums' new formulation offers a key advantage over traditional Hydroxyurea solution that require refrigeration between 2–8°C.

Akums' breakthrough aligns with India's National Sickle Cell Anemia Mission, spearheaded by Prime Minister Narendra Modi, which aims to enhance the quality of life for SCD patients by improving treatment options.

In comparison to Hydroxy Urea Capsule (500mg), Akums Hydroxy Urea suspension offers dose flexibility based on body weight of the SCD patients, thus offering significant advantage for paediatric and adolescent patients. 

The patented formulation will now come at a fraction of the cost of imported Hydroxyurea solution. With this new patent, Akums continues to advance healthcare through innovation, ensuring life-saving treatments reach those who need them the most.